Comparable stake leader
Avidity Partners Management LP
SEC ownership of Context Therapeutics Inc.
Top holders, 13D/G large-stake signals, insider positions, and transaction flow tied to CIK 0001842952.
Disclosed value leader
Avidity Partners Management LP
Comparable rows
50/50
Latest evidence
30 Jun 2026
- Public ticker
- CNTX on Nasdaq
- Parsed ownership sources
-
13D/G, 13F, and 3/4/5
Source: Parsed SEC ownership filingsUse: Compare filing families carefully
- Largest SEC-reported holder
-
Avidity Partners Management LP
Ranking: Comparable ownership first, then disclosed value
- Comparable ownership rows
-
50 of 50
Meaning: Rows with safely comparable ownership %
- Latest 13D/G holder
-
Avidity Partners Management LP
Source: Latest parsed Schedule 13D/G stake
- Latest parsed ownership date
-
30 Jun 2026
Freshness: Most recent filing date in this holder set
- Issuer CIK
- 0001842952
- Issuer location
- Philadelphia, PA
Ownership snapshot
CIK-linked ownership evidence from parsed SEC filings.
3 signals
Issuer
Names, identifiers, and filing context for this profile.
2 identity fields
Ownership snapshot
Top shareholders of Context Therapeutics Inc. (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
Avidity Partners Manageme...
Disclosed value leader
Avidity Partners Manageme...
Comparable rows
50/50
Latest evidence
30 Jun 2026
13D/G
13F
3/4/5
Lead comparable stake: 8.7%
13D/G row: Avidity Partners Management LP
Showing 1-8 of 50 holder rows.
Quick read
Avidity Partners Management LP leads the comparable SEC ownership view at 8.7%.
50 of 50 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Open SEC evidence
Opens Avidity Partners Management LP's linked filing trail.
Comparable ownership
Top 5
Avidity Partners Management LP
8.7%
Deep Track Capital, LP
8.3%
Soleus Capital Master Fund, L.P.
7.6%
BlackRock, Inc.
6.7%
FRANKLIN RESOURCES INC
4.5%
Ownership % is shown only when SEC disclosures are safely comparable across share classes.
Detailed SEC evidence table Showing 1-8 of 50 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| Avidity Partners Management LP |
13D/G
13F
Company
|
8.7%
|
$21,753,357
8,302,808 shares
|
-$2,352,163 | 31 Mar 2026 |
| Deep Track Capital, LP |
13D/G
13F
Company
|
8.3%
|
$7,419,355
7,419,355 shares
|
$0 | 31 Mar 2025 |
| Soleus Capital Master Fund, L.P. |
13D/G
|
7.6%
|
$18,243,429
6,963,141 shares
|
+$5,729,267 | 31 Mar 2026 |
| BlackRock, Inc. |
13F
13D/G
Company
|
6.7%
from 13D/G
|
$3,417,148
6,169,250 shares
|
— | 30 Jun 2026 |
| FRANKLIN RESOURCES INC |
13D/G
13F
Company
|
4.5%
|
$4,003,380
4,003,380 shares
|
$0 | 31 Mar 2025 |
| Octagon Capital Advisors LP |
13D/G
13F
Company
|
3.3%
|
$1,952,000
3,050,000 shares
|
-$1,408,000 | 30 Jun 2026 |
| Blue Owl Capital Holdings LP |
13D/G
13F
Company
|
3.2%
|
$1,877,770
2,934,015 shares
|
-$1,379,200 | 30 Jun 2026 |
| GREAT POINT PARTNERS LLC |
13D/G
|
2.4%
|
$5,864,860
2,238,496 shares
|
-$6,406,463 | 31 Mar 2026 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
Forms 3/4/5 flow
Insider trading overview
Insider buy and sell flow is broadly balanced over the last 12 months. No Buy or Sell transactions have been reported since 22 Aug 2025.
Buys
$0
Insiders: 0
Sells
$0
Insiders: 0
Net
$0
Shares: 0
Window
Last 12 months
4 rolling buckets
Buy value
Sell value
Shares: 0
Shares: 0
| Window (months) | Buy shares | Sell shares | Buy value | Sell value | Net value |
|---|---|---|---|---|---|
| 0-3 | 0 | 0 | $0 | $0 | $0 |
| 3-6 | 0 | 0 | $0 | $0 | $0 |
| 6-9 | 0 | 0 | $0 | $0 | $0 |
| 9-12 | 0 | 0 | $0 | $0 | $0 |
Reporting owners
Insider holders from Forms 3/4/5
Showing 1-15 of 15 reporting-owner rows connected to Context Therapeutics Inc.. Open a relationship link for the CIK-to-CIK filing trail.
Rows
15
Largest Forms 3/4/5 holder
Martin A. Lehr
Net 12M change
$0
Latest report
24 Jun 2026
| Name | Relationship | Holdings Value | Past Year Net Change | Change % | Valuation | Report Date |
|---|---|---|---|---|---|---|
| Martin A. Lehr | Chief Executive Officer, Director | $769,435 | Mixed | 19 Feb 2026 | ||
| Alex C. Levit | Chief Legal Officer, Corp. Sec | $58,030 | Mixed | 19 Feb 2026 | ||
| Lynn Minai Azary | Chief Financial Officer | $50,966 | Filing P/S | 19 Feb 2026 | ||
| Tarek Sahmoud | Chief Medical Officer | $8,415 | Mixed | 16 Aug 2022 | ||
| Andy Pasternak | Director | Mixed | 24 Jun 2026 | |||
| Jennifer Evans Stacey | Director | Mixed | 24 Jun 2026 | |||
| Philip W. Kantoff | Director | Mixed | 24 Jun 2026 | |||
| Linda West | Director | Mixed | 24 Jun 2026 | |||
| William F. Rencher | Former Section 16 officer | Mixed | 15 Feb 2022 | |||
| Evan G. Dick | Former Section 16 officer | Mixed | 15 Feb 2022 | |||
| Karen Deborah Chagin | Chief Medical Officer | Mixed | 19 Feb 2026 | |||
| Richard J. Berman | Director | Mixed | 13 Jun 2024 | |||
| Ullmann Claudio Dansky | Chief Medical Officer | Mixed | 13 Feb 2025 | |||
| Luke Nathaniel Walker | Director | Mixed | 24 Jun 2026 | |||
| Karen L. Smith | Director | Mixed | 24 Jun 2026 |
Recent insider transactions for Context Therapeutics Inc.
Showing up to 300 recent insider transactions from the last 12 months.
| Insider | Symbol | Class | Transaction | % | SEC-reported value | SEC-reported price | Shares | Shares owned | Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|---|
| Andy Pasternak | CNTX | Stock Option (right to buy) | Award | 45,000 | 45,000 | 24 Jun 2026 | Direct | |||
| Jennifer Evans Stacey | CNTX | Stock Option (right to buy) | Award | 45,000 | 45,000 | 24 Jun 2026 | Direct | |||
| Linda West | CNTX | Stock Option (right to buy) | Award | 45,000 | 45,000 | 24 Jun 2026 | Direct | |||
| Karen L. Smith | CNTX | Stock Option (right to buy) | Award | 45,000 | 45,000 | 24 Jun 2026 | Direct | |||
| Luke Nathaniel Walker | CNTX | Stock Option (right to buy) | Award | 45,000 | 45,000 | 24 Jun 2026 | Direct | |||
| Philip W. Kantoff | CNTX | Stock Option (right to buy) | Award | 45,000 | 45,000 | 24 Jun 2026 | Direct | |||
| Alex C. Levit | CNTX | Stock Option (right to buy) | Award | 270,000 | 270,000 | 19 Feb 2026 | Direct | |||
| Lynn Minai Azary | CNTX | Stock Option (right to buy) | Award | 275,000 | 275,000 | 19 Feb 2026 | Direct | |||
| Karen Deborah Chagin | CNTX | Stock Option (right to buy) | Award | 290,000 | 290,000 | 19 Feb 2026 | Direct | |||
| Martin A. Lehr | CNTX | Stock Option (right to buy) | Award | 815,000 | 815,000 | 19 Feb 2026 | Direct |
* marks a reported price that did not pass the local price check.